Abstract:Objective To evaluate the clinical results of treatment for osteosarcoma of the extremities with adjuvant chemotherapy regimen Methods Sixty seven patients with ⅡB extremity osteosarcoma were treated with the combination of adjuvant chemotherapy regimen and definitive surgery Forty seven of them were male and twenty four were female The mean age of the patients at the time of diagnosis was 20 years (ranged 10～51 years) Sixty four lesions involved the lower extremity, with 45 involving the distal femur, 14 the upper tibia, 3 the upper fibula and 2 the proximal femur; Three involved the upper end of the humerus The study of subtype of osteosarcoma revealed that 51 were osteoblastic, 6 chondroblastic, 5 fibroblastic and 5 the other subtypes The patients were divided into three groups according to the adjuvant chemotherapy regimen given, the first group consisted of 23 cases, who were treated with the combination of the presurgical cisplatin hyperthermic isolated limb perfusion (CDP-HILP) and postoperative chemotherapy; the second group of 20 cases, who were treated with the combination of the presurgical CBP-HILP and postoperative chemotherapy; and the other 24 cases were treated with postoperative chemotherapy alone Twenty nine of the 67 patients treated surgically had limb salvage procedures; 35 had amputations and 3 had Tikhoff-Limbergs surgery Multiple histologic sections were procured and examined from each of the surgical specimens in the patients who were treated with preoperative HILP to determine the effect of chemotherapy All patients were followed from 3 to 9 years, and the data were statistically analeyed using SPSS 7 0 Results Among 67 cases, 41 (61 19%) had relapse free survival(RFS) in 2 years after surgery, 37 (55 22%) had RFS in 3 years after surgery, and RFS probability at 5 years after surgery was 49 56% Log-rank analysis showed no significant difference in RFS probability among the three groups(P=0 517 1), but there was a significant difference in RFS probability between patients who had limb salvage procedure and those had amputation(P=0 009 7) Age, sex, site and subtype were not significant prognostic variables in this group of patients Correction analysis revealed that the RFS probability were not related with the rate of the tumor necrosis (P=0 058) Conclusion The data revealed that 1) The chemotherapy regimen mainly including platinic drugs was effective treatment for osteosarcoma ,and was more simple and less expensive than any previous reported chemotherapy for steosarcoma, 2) CDP of chemotherapy regimen for osteosarcoma, which had more nephritic and audio toxicity could be replaced by CBP , And 3)Whether the preoperative chemotherapy is suitable for the patients in whom amputation is inevitable (based on age ,size, and involvement of local structure) remains unclear

Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma

Progress in the Chemotherapeutic Treatment of Osteosarcoma (Review)

Current and future therapeutic approaches for osteosarcoma

Future Directions in the Treatment of Osteosarcoma

Translational biology of osteosarcoma

Current Status and Prospects of Clinical Treatment of Osteosarcoma

Novel Immunotherapies for Osteosarcoma

Anti-Angiogenesis Target Therapy for Advanced Osteosarcoma

Advancing therapy for osteosarcoma

Advances in Bone‐targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma

Molecular targeted therapy of osteosarcoma and related clinical

T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

A Meta-Analysis of the Efficacy and Safety of First-Line Chemotherapeutic Agents for Osteosarcoma.

Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments

Targeted anti-angiogenesis therapy for advanced osteosarcoma

Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies

Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)

Osteosarcoma and Metastasis

Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies